Premium
A double‐blind study on clonazepam in patients with burning mouth syndrome
Author(s) -
Heckmann Siegfried M.,
Kirchner Elena,
Grushka Miriam,
Wichmann Manfred G.,
Hummel Thomas
Publication year - 2012
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.22490
Subject(s) - clonazepam , burning mouth syndrome , placebo , medicine , anesthesia , placebo group , randomized controlled trial , clinical trial , depression (economics) , orofacial pain , physical therapy , alternative medicine , pathology , economics , macroeconomics
Objectives/Hypothesis: In the treatment of burning mouth syndrome (BMS), various approaches have been tried with equivocal results. The aim of the present randomized clinical trial was to determine the efficacy of clonazepam, a GABA agonist designed as an antiepileptic drug that exerts the typical effects of benzodiazepines. Study Design: Randomized clinical trial. Methods: Twenty patients with idiopathic BMS were carefully selected. Clonazepam (0.5 mg/day, n = 10) or placebo (lactose, n = 10) were randomly assigned to the patients. Results: Patients on clonazepam significantly improved in pain ratings ( P < .001). These changes were less pronounced in the placebo group ( P < .11). No significant changes were observed in a mood scale ( P = .56) or for depression scores ( P = .56). Taste test and salivary flow increased over sessions, but were not different between groups ( P = .83 and P = .06, respectively). Conclusions: Clonazepam appears to have a positive effect on pain in BMS patients. Laryngoscope, 2012
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom